Skip to content
lifestyle.recentlegalnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
April 15, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
April 9, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
March 23, 2026
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
February 25, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
February 17, 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
February 11, 2026